Reorienting our view of particle-based adjuvants for subunit vaccines

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 4, 2012, Pages 999-1000

  Little, Steven R ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; SUBUNIT VACCINE;

HELPER CELL; NONHUMAN; NOTE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL;

ANTIGENS, PROTOZOAN; B-LYMPHOCYTES; MALARIA VACCINES; NANOPARTICLES; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84856397770     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1120993109     Document Type: Note

References (14)

1. Price RN, Douglas NM, Anstey NM (2009) New developments in Plasmodium vivax malaria: Severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 22:430-435.
2. Bell BA, et al. (2009) Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 27:1448-1453.
3. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: Putting innate immunity to work. Immunity 33:492-503.
4. Moon JJ, et al. (2012) Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci USA 109:1080-1085.
5. Hirosue S, Kourtis IC, van der Vlies AJ, Hubbell JA, Swartz MA (2010) Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 28:7897-7906.
6. Little SR, et al. (2004) Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci USA 101:9534-9539. (Pubitemid 38869271)
7. Moon JJ, et al. (2011) Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 10:243-251.
8. Liu W, Chen Y-H (2005) High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: A novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol 35:505-514. (Pubitemid 40331328)
9. Baumgartner CK, Malherbe LP (2010) Regulation of CD4 T-cell receptor diversity by vaccine adjuvants. Immunology 130:16-22.
10. Evans JT, et al. (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2:219-229. (Pubitemid 36559927)
11. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9:287-293.
12. Gowda DC (2007) TLR-mediated cell signaling by malaria GPIs. Trends Parasitol 23:596-604.
13. Mockenhaupt FP, et al. (2006) Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 103:177-182. (Pubitemid 43076124)
14. Champion JA, Mitragotri S (2006) Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 103:4930-4934.